New study results confirm the value of calprotectin in management of COVID-19 patients

20. Nov 2020 | 5 min read

New study results confirm the value of calprotectin in management of COVID-19 patients

New study results from a study conducted in collaboration with Charité – Universitätsmedizin Berlin and Labor Berlin have been published in the Letter to the Editor in the scientific journal “Journal of Infection” [1]. The study has evaluated the performance of calprotectin in prediction of severe events e.g. admission to intensive care unit (ICU), multiorgan failure (MOF) and mortality in COVID-19 patients presented at the Emergency Department (ED).

66 patients presented to the ED with suspected Sars-CoV-2 infection were prospectively enrolled in the study. Using PCR testing in pharyngeal swabs, 47 patients tested as negative, and 19 patients were diagnosed with COVID-19. The performance of calprotectin was compared with the performance of routinely used biomarkers: lactate, C-reactive protein (CRP) and procalcitonin (PCT).

The study results show high performance of calprotectin in prediction of MOF and admission to the ICU, and it also suggests calprotectin as a valuable biomarker for early management in COVID-19 patients evaluated in the ED. The authors conclude that the data strongly argue that calprotectin might represent an addition to the biomarker repertoire in the ED, since it seems to perform better than traditional biomarkers.

The conclusion from this study supports calprotectin as a novel and useful discriminator in COVID-19 patients admitted to the ED, with respect to disease outcome, e.g. MOF and ICU admission, and calprotectin measurement in blood samples being easily applicable in routine laboratories.

Several recent studies have reported increased levels of calprotectin in patients with severe SARS-Cov-2 infection, as well as the possibility of calprotectin to differentiate between mild and severe forms of the disease, and its ability to predict the need for mechanical ventilation and mortality [2-6]:

  1. Wolfgang Bauer, Eva Diehl-Wiesenecker, Jannis Ulke, Noa Galtung, Aleksandra Havelka, J. Kolja Hegel, Rudolf Tauber, Rajan Somasundaram, Kai Kappert, Outcome prediction by serum calprotectin in patients with COVID-19 in the emergency department, Journal of Infection (2020). 
  2. de Guadiana Romualdo LG et al. (2020). Circulating levels of GDF-15 and calprotectin for prediction of in-hospital mortality in COVID-19 patients: a case series. Journal of Infection 
  3. Shi H et al. (2020). Neutrophil calprotectin identifies severe pulmonary disease in COVID-19. Journal of Leukocyte Biology 
  4. Silvin et al. (2020). Elevated calprotectin and abnormal myeloid cell subsets discriminate severe from mild COVID-19. Cell
  5. Sohn KM et al. (2020). COVID-19 Patients Upregulate Toll-like Receptor 4-mediated Inflammatory Signaling That Mimics Bacterial Sepsis. J Korean Med Sci. 
  6. Wu M et al. (2020). Transcriptional and proteomic insights into the host response in fatal COVID-19 cases. PNAS 

Download press release

 

New call-to-action

For further information, please contact:

Hilja Ibert CEO, Gentian Diagnostics
E-mail: 
hilja.ibert@gentian.no 
Cell Phone: +47 919 05 242

 

Njaal Kind CFO, Gentian Diagnostics
E-mail: 
njaal.kind@gentian.no
Cell Phone: +47 919 06 525

 

https://newsweb.oslobors.no/message/518606 
https://www.gentian.com/investor-relations-stock-information/investors-news/new-study-results-confirm-the-value-of-calprotectin-in-management-of-covid-19-patients 

You may also read


The utility of the cystatin C test in diagnosing kidney disease

May 12, 2021

The utility of the cystatin C test in diagnosing kidney disease

Webinar about cystatin C as an alternative to creatinine In this exciting webinar a multidisciplinary panel..

Calprotectin blood test - FAQ series

May 05, 2021

Calprotectin blood test - FAQ series

Plasma and serum calprotectin In our Frequently Asked Questions about calprotectin series we will answer..